About SPRAVATO™

See the SPRAVATO™ Story

The first and only NMDA receptor antagonist approved for TRD in adults1

SPRAVATO™ hypothesized mechanism of action


SPRAVATO™ clinical program overview

Studied in more than 1700 adult patients with treatment-resistant depression1

BASELINE PSYCHIATRIC PATIENT CHARACTERISTICS1,2

COMPARED TO PLACEBO NASAL SPRAY + ORAL AD1

References

1.SPRAVATO™ [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. March 2019.

2.Data on file. Janssen Pharmaceuticals, Inc. Titusville, NJ.